MedPath

Bristol Myers Squibb Presents New COBENFY Data for Schizophrenia Treatment at Psych Congress

• Bristol Myers Squibb is presenting new data at Psych Congress highlighting the clinical profile of COBENFY (xanomeline and trospium chloride) for schizophrenia. • Data from the EMERGENT clinical trial program demonstrates COBENFY's efficacy, safety, and patient-reported outcomes in adults with schizophrenia. • Presentations include long-term safety and efficacy results, patient satisfaction, and quality of life improvements with xanomeline and trospium chloride. • Additional research covers health economics, real-world data on negative symptoms and cognitive impairment, and comparative efficacy against atypical antipsychotics.

Bristol Myers Squibb (BMS) is presenting new clinical data and health economics and outcomes research on COBENFY™ (xanomeline and trospium chloride) at Psych Congress. The presentations will highlight the differentiated clinical profile of COBENFY, including efficacy, safety, and patient-reported outcomes in adults with schizophrenia who participated in the EMERGENT clinical trial program.

COBENFY Data Presentations

Several poster presentations will feature data from the EMERGENT trials, including:
  • Long-Term Safety and Efficacy: Results from the 52-week, open-label EMERGENT-4 and EMERGENT-5 trials will be presented, detailing the long-term safety, tolerability, and efficacy of xanomeline and trospium chloride in patients with schizophrenia.
  • Patient-Reported Outcomes: Qualitative interview-based studies will explore patient satisfaction and changes in quality of life among schizophrenia outpatients receiving xanomeline and trospium chloride.
  • Efficacy Analyses: Post hoc analyses of pooled data from three 5-week, randomized, double-blind, placebo-controlled EMERGENT trials will examine the efficacy of xanomeline and trospium chloride.
  • Agitation Reduction: Data from three randomized, double-blind, placebo-controlled trials will assess the impact of xanomeline and trospium chloride on agitation in schizophrenia, measured by the PANSS-EC.
  • Metabolic Outcomes: Interim results from pooled, long-term safety studies EMERGENT-4 and EMERGENT-5 will provide insights into the long-term metabolic outcomes associated with xanomeline and trospium chloride.
  • Participant Experience: In-trial qualitative interviews will explore participant experiences with xanomeline and trospium chloride treatment, focusing on perceived effects on symptoms during a long-term Phase 3 trial.

Health Economics and Outcomes Research

Presentations on health economics and outcomes research include:
  • Real-World Data: A descriptive study using the NeuroBlu database will examine negative symptoms and cognitive impairment in US patients with schizophrenia.
  • Network Meta-Analysis: A network meta-analysis will compare the efficacy, safety, and tolerability of xanomeline and trospium chloride versus eight atypical antipsychotics for the acute treatment of adults with schizophrenia.
  • Epidemiology: Current estimates of the incidence and prevalence of schizophrenia in the U.S. will be presented.

About COBENFY (xanomeline and trospium chloride)

COBENFY is an oral medication indicated for the treatment of schizophrenia in adults. It combines xanomeline, a dual M1- and M4-preferring muscarinic receptor agonist, with trospium chloride, a muscarinic receptor antagonist that primarily confines its effects to peripheral tissues. The efficacy of COBENFY is thought to be due to the agonist activity of xanomeline at M1 and M4 muscarinic acetylcholine receptors in the central nervous system.

Schizophrenia: A Significant Global Health Issue

Schizophrenia is a persistent and often disabling mental illness affecting nearly 24 million people worldwide, including 2.8 million in the United States. It is characterized by positive symptoms (e.g., hallucinations, delusions), negative symptoms (e.g., lack of motivation, social withdrawal), and cognitive dysfunction (e.g., impaired attention, memory deficits). These symptoms can significantly impact a person's ability to maintain employment, live independently, and manage relationships.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Cobenfy Shows Cognitive Benefits in Schizophrenia Patients with CANTAB Assessment

Cobenfy, a novel schizophrenia treatment targeting M1/M4 muscarinic receptors, has received FDA approval and demonstrates efficacy in reducing both positive and negative symptoms.
A post-hoc analysis of Phase 3 trials using Cambridge Cognition's CANTAB reveals cognitive performance improvements in schizophrenia patients with pre-existing cognitive impairment.

FDA Approves Cobenfy, a Novel Schizophrenia Treatment Targeting Cholinergic Receptors

The FDA approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride) as the first schizophrenia treatment to target cholinergic receptors, offering a new mechanism of action.
Cobenfy's approval marks a significant breakthrough, potentially improving both psychotic and cognitive symptoms by targeting muscarinic M1 and M4 receptors in the brain.

AbbVie's Emraclidine Fails, Bolstering BMS's Lead in Schizophrenia Treatment

AbbVie's emraclidine failed to demonstrate statistically significant improvement in schizophrenia symptoms in Phase II trials, a setback for the muscarinic pathway approach.
Bristol Myers Squibb's Cobenfy (KarXT), a muscarinic agonist, now stands as the frontrunner in schizophrenia treatment after AbbVie's trial failures.

Cobenfy Approved for Schizophrenia: A Novel Muscarinic Receptor Agonist

Cobenfy (KarXT), developed by Bristol Myers Squibb, has been approved by the FDA as a novel antipsychotic medication for schizophrenia.
Cobenfy represents a potential breakthrough due to its unique mechanism targeting muscarinic receptors, unlike older drugs that block dopamine.

FDA Approves Cobenfy, a Novel Muscarinic Receptor-Targeting Drug for Schizophrenia

The FDA has approved Cobenfy (xanomeline-trospium), the first new mechanism of action in schizophrenia treatment in over 70 years, targeting muscarinic cholinergic receptors.
Cobenfy combines xanomeline, a muscarinic M1/M4 receptor agonist, with trospium, a pan-muscarinic antagonist, to mitigate peripheral side effects.

AbbVie's Emraclidine Fails Phase 2 Schizophrenia Trial, Boosting Bristol Myers Squibb's Cobenfy

AbbVie's emraclidine did not meet the primary endpoint in a Phase 2 trial for schizophrenia, showing no statistically significant improvement over placebo.
Analysts suggest this failure removes a major competitive threat for Bristol Myers Squibb's recently approved schizophrenia drug, Cobenfy (KarXT).

Cobenfy: A Novel Schizophrenia Treatment Approved by FDA

The FDA approved Cobenfy (xanomeline and trospium chloride) as a first-in-class treatment for schizophrenia, offering a new mechanism of action.
Cobenfy targets cholinergic receptors, unlike traditional dopamine receptor-targeting drugs, potentially reducing adverse side effects.

FDA Approves Cobenfy for Schizophrenia with Novel Mechanism and Fewer Side Effects

The FDA has approved Bristol Myers Squibb's Cobenfy for schizophrenia, highlighting its potential for fewer side effects compared to existing treatments.
Cobenfy targets a different receptor to indirectly modulate dopamine release and includes ingredients to mitigate common side effects like nausea and weight gain.

Cobenfy Demonstrates Sustained Efficacy in Long-Term Schizophrenia Treatment

Cobenfy (xanomeline and trospium chloride) shows sustained improvements in schizophrenia symptoms over 52 weeks in Phase III trials.
The EMERGENT-4 and EMERGENT-5 trials highlight Cobenfy's efficacy in reducing PANSS total scores and improving CGI-S scores.

Cobenfy Shows Mixed Results in Schizophrenia Trials, High Dropout Rates Highlight Treatment Challenges

Cobenfy, a novel schizophrenia drug, demonstrated symptom improvement in some patients, but high dropout rates in trials underscore challenges in treating the illness.
A study of severely ill patients showed 69% experienced meaningful symptom improvement after one year, while a study of more stable patients showed 30% benefit.

Reference News

[1]
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes ...
finance.yahoo.com · Oct 28, 2024

Bristol Myers Squibb presents COBENFY data at Psych Congress, highlighting efficacy, safety, and patient outcomes in sch...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy